Search results: (10000)
News Where radical surgery cannot be performed in the subhepatic region or liver, there is room for radiation treatment
Proton radiotherapy continues to expand its indications in the treatment of oncological diseases. In the following interview, we focus on its role in treating tumors in the subhepatic region. MUDr. Pavel Vítek, Ph.D., MBA, from the Proton Center Prague (PTC), shared his perspective on this modality and his experiences at his workplace.
News Noonan Syndrome (Not Just) in the Pediatric Cardiologist's Office
Noonan Syndrome (NS) is a genetically determined disease associated with a high prevalence of (not just) congenital heart defects. When is it necessary to consider it in a cardiologist's office, where to refer the patient if suspected, and how to proceed if the diagnosis is confirmed?
News Care of Dental Dentures According to the Recommendations of the American Society of Dental Prosthetists
Dental dentures are the most common solution for missing teeth in the jaw. They should serve patients for several years, so proper care is essential. Therefore, dental professionals should not only be able to make them perfectly but also provide their patients with quality information about their maintenance. However, individual experts often differ in their recommendations, advising based on their own experiences, and even national dental organizations do not always have these information easily accessible. The American Society of Dental Prosthetists has therefore issued a series of recommendations that can be followed by both doctors and patients or caregivers.
News Dressing Solutions for Better Wound Care
Although wounds at different stages of healing require different types of treatment, the essential part of any dressing change is cleaning the wound and its surroundings from tissue debris and microorganisms and protecting it from reinfection. Modern dressing solutions facilitate easy cleaning and moisturizing of wounds. Effective treatment also brings clinical and economic benefits.
News Recommendations for Nutrition of Patients at Risk of or with Pressure Ulcers
Nutrition plays a crucial role in the prevention and treatment of pressure ulcers. In 2019, international recommendations for the nutrition of individuals at risk of or already with pressure ulcers were developed. Based on published evidence, they were prepared by expert groups PUAP/NPIAP/PPPIA (Pressure Ulcer Advisory Panel, National Pressure Injury Advisory Panel, Pan Pacific Pressure Injury Alliance Prevention) as a clinical practice guide for doctors and nurses.
News Importance of Home Parenteral Therapy: ESPEN Recommendations from 2020
Home parenteral therapy currently plays a crucial role in the treatment and prevention of malnutrition in specific patient groups. The European Society for Clinical Nutrition and Metabolism (ESPEN) published updated guidelines for home parenteral therapy in 2020, based on current evidence and expert recommendations.
News Which biomarkers can be used for risk stratification in ATTR cardiac amyloidosis?
Effective treatment for patients with transthyretin cardiac amyloidosis requires timely diagnosis and precise risk stratification to identify patients at higher risk of cardiovascular events, heart failure progression, and death. Currently, there are several scoring systems based on commonly available laboratory parameters. Here is a brief overview.
News Combined Hormonal Contraception in the Treatment of Dysmenorrhea
Dysmenorrhea troubles many women of reproductive age and can deteriorate their quality of life, making it important for doctors to offer suitable therapy. We summarize the findings of research on the use of hormonal contraception containing drospirenone (DRSP) and ethinylestradiol (EE) in the treatment of dysmenorrhea.
News Efficacy of Dabigatran on Left Atrial Appendage Thrombus in Patients with Atrial Fibrillation
The direct thrombin inhibitor dabigatran has shown interesting efficacy in a smaller clinical study in patients with atrial fibrillation and a thrombus in the left atrial appendage. Chinese authors evaluated the results of anticoagulant therapy using transthoracic and transesophageal echocardiography.
News H₂FPEF Score for Estimating the Probability of Heart Failure with Preserved Ejection Fraction in Persons with Unexplained Dyspnea
The simple, validated H₂FPEF scoring system based on clinical and echocardiographic parameters, developed by experts from the Mayo Clinic, allows the differentiation of heart failure with preserved ejection fraction (HFpEF) from dyspnea of other etiologies and helps decide whether further examinations are necessary. The score can be calculated online and in the Czech language.
News A Brief History of Deep Vein Thrombosis Treatment – From Antiquity to the Present
Deep vein thrombosis is among the common diseases that have accompanied humanity since its inception. Due to the low specificity of its clinical presentation (in contrast to, for example, varicose veins of the lower limbs), however, the disease long went undescribed in literature. The first descriptions of deep vein thrombosis did not appear until the Middle Ages – and from that moment, the gradual development of its treatment began. We offer you a brief but remarkable historical excursion in three stages.
News OCA in Second-Line Treatment of PBC: Analysis Results and Real-World Data
Ursodeoxycholic acid (UDCA) is the cornerstone treatment for PBC according to the guidelines of the European Association for the Study of the Liver (EASL). However, many patients (25–50%) do not achieve an adequate response to it, and some patients develop intolerance leading to the necessity of discontinuation (in the phase III POISE study, this concerned 7% of participants). Then, obeticholic acid (OCA) is indicated, which is recommended as the only registered second-line treatment option for PBC by current professional guidelines both European (EASL 2017) and Czech (2018). The latest data on OCA from clinical studies as well as real-world practice was also presented at this year's XLVIII May Hepatology Days.
News Effect of Azacitidine in the Treatment of Acute Myeloid Leukemia on Long-Term Patient Survival
The work cited below presents freshly updated results from the Quazar AML-001 study evaluating azacitidine (AZA) in the treatment of acute myeloid leukemia (AML), now with a median follow-up period of 55.5 months. Among other things, clinical and biological variables predictive of long-term survival, defined here as survival ≥ 3 years from randomization within the study, were examined.
News Prediabetes through the lens of current data and findings − and why hurry with intervention
Type 2 diabetes mellitus (DM2) is one of the most common causes of premature morbidity and mortality worldwide. The most serious impact on the health of the organism is mainly due to the macrovascular complications of this disease. However, their occurrence was often recorded before the diagnosis of DM2 was confirmed. Prediabetes itself thus represents a condition associated with the risk of developing cardiovascular (CV) complications with all their prognostic implications for patients.
News Diosmin – Still an Important Modality in the Treatment of Venous Insufficiency
Chronic venous insufficiency is a highly prevalent disease in the Western population. Unfortunately, it remains without causal treatment. In the recommended therapeutic procedures, especially in the initial stages, compression treatment supplemented with pharmacotherapy plays a key role. This includes the administration of medicinal products containing micronized diosmin. The following text summarizes basic findings about its properties that predispose it to clinical use.
News Fresh from ASH 2021: Promising results of the combination of azacitidine with venetoclax and magrolimab in the treatment of AML
Dr. Naval Daver and his colleagues from the Anderson Cancer Center in Houston presented an oral report during the December congress of the American Society of Hematology (ASH 2021) about a phase Ib/II study that evaluated the effects of the combination of azacitidine (AZA) + venetoclax (VEN) + magrolimab (magro) in various types of patients with acute myeloid leukemia (AML) – newly diagnosed in older or unfit individuals, high-risk, or relapsed/refractory cases (R/R AML).
News Prophylaxis with Enoxaparin After Total Knee or Hip Replacement
Venous thromboembolic disease is a significant cause of complications in surgical patients during and after hospitalization. The authors of a recently published Portuguese observational study evaluated the incidence of complications with prophylaxis using low-molecular-weight heparin (LMWH) enoxaparin in a population after hip or knee joint replacement.
News Early Implementation of Highly Effective Therapy for Multiple Sclerosis
The ongoing debate about changing the approach to treating relapsing-remitting multiple sclerosis (RRMS) from an escalation strategy to the early implementation of highly effective therapy (HET) is based on the documented high inflammatory activity of the disease in its early stages and the concept of a therapeutic window for its suppression shortly after diagnosis. We bring you a summary of several recent pieces of information about the benefits and safety of HET as an initial treatment for RRMS.
News Comparison of Three Thromboprophylactic Regimens in Patients Post Pancreatic Surgery
Post-pancreatectomy bleeding and thromboembolic disease are among the serious complications of pancreatic surgeries. The aim of the study published last year in the British Journal of Surgery was to compare the efficacy and safety of different dosing regimens of low-molecular-weight heparin nadroparin in patients undergoing oncologic pancreatic surgery.
News Recommend Erdostein for children when treating with amoxicillin – symptoms of cough improve in almost 50% of cases within 3 days
Acute respiratory infections are usually treated empirically in primary care as the causative agent is not known. Amoxicillin is among the most commonly chosen antibiotics. Erdostein is a suitable addition to this antibiotic treatment for several reasons.
News Chemoimmunotherapy in the Treatment of Breast Cancer − Final Results of the IMpassion130 Study
According to international recommendations, treatment with the immune checkpoint inhibitor atezolizumab in combination with the cytostatic nab-paclitaxel is used for patients with locally advanced or metastatic breast cancer where PD-L1 protein expression is detected on the surface of tumor-infiltrating immune cells (IC). The final results regarding overall survival and long-term safety of this treatment in patients who participated in the registration study IMpassion130 were presented at this year's European Society for Medical Oncology (ESMO) congress, which was held virtually due to circumstances.